Comparative Real-World Effectiveness of Biologic Therapies for Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
Authors:
- Newaz Shubidito AhmedNANewaz Shubidito Ahmed
- Rakhbeer BoparaiRBRakhbeer Boparai
- Mashal FidaMFMashal Fida
- Christine WangCWChristine Wang
- Ashley N. ClarkeACAshley N. Clarke
- Nima HamidiNHNima Hamidi
- Anthony R. MacleanAMAnthony R. Maclean
- William Donald BuieWBWilliam Donald Buie
- Mark S. SilverbergMSMark S. Silverberg
- Paulo G. KotzePKPaulo G. Kotze
- Cathy LuCLCathy Lu
- Kerri L. NovakKNKerri L. Novak
- 18 September 2026
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Abstract
BACKGROUND: Postoperative recurrence is common after ileocolonic resection for Crohn's disease (CD). Comparative effectiveness data for advanced treatments for preventing recurrence are limited. METHODS: We conducted a population-based retrospective cohort study of adults with CD undergoing ileocolonic resection with primary anastomosis in the Calgary Health Zone, Canada (2016–2020). The primary outcome was endoscopic recurrence within 18 months, assessed using the modified Rutgeerts score as an ordinal endpoint. High-risk recurrence (modified Rutgeerts score ≥ i2b) was evaluated as a secondary outcome. Propensity scores were estimated using established clinical risk factors, and inverse probability of treatment weighting targeting the average treatment effect among treated patients was applied to ordinal and logistic regression models. Treatment effects were expressed as adjusted odds ratios (aOR) with 95% CI. RESULTS: Among 231 patients, 126 (54.5%) received biologic prophylaxis and 92 (39.8%) received no treatment; endoscopy was performed in 217 patients. High-risk endoscopic recurrence occurred in 42.3% (36/85) of untreated patients compared with 9.4% (6/64) receiving tumor necrosis factor (TNF) antagonists, 27.8% (10/36) receiving ustekinumab, and 9.5% (2/21) receiving vedolizumab. After weighting for established risk factors for recurrence, all biologic strategies were associated with reduced odds of endoscopic recurrence compared with no treatment (aOR 0.15–0.31, all P < 0.05). Vedolizumab was associated with lower odds of recurrence compared with ustekinumab (aOR 0.24 [0.06–0.92], P = 0.04) but not TNF antagonists (aOR 0.43 [0.10–1.87], P = 0.26). DISCUSSION: In this real-world cohort, biologic prophylaxis is associated with reduced endoscopic recurrence in CD. Both ustekinumab and vedolizumab are effective options, including after prior TNF exposure.Keywords
This publication has 30 references indexed in Scilit:
- Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort studyThe Lancet Gastroenterology & Hepatology, 2025
- Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet Gastroenterology & Hepatology, 2024
- Prevention of post-operative recurrence of Crohn's disease among patients with prior anti-TNFα failure: A retrospective multicenter studyDigestive and Liver Disease, 2022
- Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryDigestive and Liver Disease, 2022
- Advances in the Comprehensive Management of Postoperative Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2022
- Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-Based CohortsClinical Gastroenterology and Hepatology, 2021
- Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's diseaseUnited European Gastroenterology Journal, 2021
- Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn’s Recurrence: Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2021
- Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2020
- Crohn's disease management after intestinal resection: a randomised trialThe Lancet, 2015